-
LHNVD-105, a universal influenza vaccine, showed strong immunogenicity at low doses in pigs, validating previous studies in rodents
-
Monoclonal antibodies generated by LHNVD-105 demonstrate the need to target multiple distinct conserved regions on influenza viruses
-
LHNVD-301, a monoclonal antibody cocktail targeting heat shock proteins, exhibits potent activity against clinical tuberculosis isolates
Bethesda, MD and Gaithersburg, MD, April 27, 2024–(BUSINESS WIRE)–Longhorn Vaccine and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonotic disease concerns. Nostyx presented positive data from three key studies for its infectious disease franchise at the European Society for Clinical Microbiology and the European Society for Clinical Microbiology. Infectious Diseases (ECCMID) 2024. ECCMID will be held online and in-person from April 27th to 30th, 2024 in Barcelona, Spain.
Longhorn's vaccine and antibody product candidates are focused on rapidly mutating viruses, including influenza, coronaviruses, and antibiotic-resistant pathogens. Candidates presented include LHNVD-105, an adjuvanted conjugate peptide vaccine that targets multiple steps in the viral replication process, and LHNVD-105, which targets proteins that may play a key role in keeping tuberculosis in the latent stage. Contains a monoclonal antibody cocktail.
Influenza is a prevalent zoonotic respiratory virus, and pigs act as intermediaries to generate new virus strains that can be transmitted to humans, birds, and other pigs with pandemic potential. This is a major public health issue and a challenge for the pig industry. His first of two studies on Longhorn's universal influenza vaccine, LHNV D-105, showed how his unbound, multi-epitope peptide formulated with AddaVax was used. I showed you how.TM When administered in low doses to pigs using an adjuvant, antibodies were generated that were broadly reactive across multiple influenza virus strains. Results include:
-
After a single dose, pigs immunized with LHNVD-105 produced IgG antibodies that bound to multiple strains of influenza virus 21 days after the initial immunization.
-
Pigs that received low vaccine doses (1 and 5 μg) produced binding antibodies to influenza virus that were equal to or greater than pigs in the high dose groups (50 and 100 μg).
-
No adverse reactions to the vaccine were observed.
“We are very excited to announce the first data on our universal influenza vaccine for swine,” said Jeff Fisher, president of Longhorn Vaccine and Diagnostics. “Pigs are an ideal model for influenza, and the results mirrored important rodent data published to date.”
Seasonal outbreaks of rapidly evolving influenza strains are a potential threat to human populations. For people at high risk of exposure to influenza or those with weakened immune systems, new strains resistant to antiviral therapy pose a life-threatening risk. Her second study on LHNVD-105 evaluated the binding and functional capacity of her four different isotype-specific anti-influenza mAbs in mice to determine candidates for cocktail therapy approaches against influenza. Proven results:
-
Anti-influenza mAbs LD9 (IgG1, anti-HA), NB5 (IgG2a, anti-NA), GA4 (IgG1, anti-matrix), and CG6 (IgG3, anti-matrix) bound equally well to H3N2, but unlike H3N2. and combined. Other modern and pandemic stocks.
-
Anti-HA monoclonal antibody LD9 and anti-matrix monoclonal antibody GA4 (both IgG1) bound preferentially to the pandemic H5N1 influenza strain, whereas anti-matrix monoclonal antibody CG6 was more reactive against influenza B.
-
Anti-NA monoclonal antibody NB5 and anti-matrix monoclonal antibody CG6 both showed high affinity for H3N2 and influenza B, but were less reactive against H1N1 and H5N1.
-
Neutralizing activity of all four mAbs was demonstrated against H1N1 and H3N2.
“Tuberculosis is one of the most common and deadly diseases in the world. Up to a third of the world's population is infected with tuberculosis.” Mycobacterium tuberculosis “Heat shock proteins play a critical role in protecting bacteria from the immune system and helping them survive,” said Gerald W. Fisher, MD, CEO of Longhorn Vaccines and Diagnostics. There is a possibility.” The data presented suggest that both our heat shock protein vaccine candidate and monoclonal antibody cocktail may play an important role in the prevention and treatment of multidrug-resistant tuberculosis infections. ”
Mycobacterium tuberculosis (MTB) is a virus that is becoming increasingly resistant to antibiotics and is an important pathogen contributing to antimicrobial resistance worldwide. The third study was conducted by the University of Pretoria and investigated longhorn monoclonal antibodies for the prevention and treatment of infections caused by MTB and Gram-positive bacteria. In this study, we analyzed the binding capacity of IgG2a (anti-heat shock protein (HSP16.3)) and IgG2b (anti-peptidoglycan (PGN)) mAbs against clinical MTB isolates. Results found:
-
Both IgG2a and IgG2b monoclonal antibodies showed good avidity against live and ethanol-killed MTB, as well as mid-log and stationary phase MTB.
-
This mAb showed good binding to live clinical MTB isolates even at concentrations as low as 0.25 μg/mL.
For more information about Longhorn, please visit www.LHNVD.com.
About Longhorn Vaccines and Diagnosis
Longhorn Vaccine and Diagnostics, Inc., a privately held One Health company based in Maryland, is developing broad-spectrum vaccines to address global public health concerns and prevent future pandemics. and developing diagnostic tools. Since its founding in 2006, Longhorn has focused on developing broadly applicable vaccines and diagnostic tools that have the potential to impact pandemics globally and at all socio-economic levels. As pandemics occur between humans and animals, Longhorn products play a critical role in monitoring, diagnosing, preventing and treating the following infectious diseases:
View source version on businesswire.com. https://www.businesswire.com/news/home/20240427410246/en/
contact address
Longhorn Vaccines and Diagnostics LLC
Jeffrey Fisher
Email: jeff@lhnvd.com
media
Alexis Feinberg – ICR Westwick PR
Email: alexis.feinberg@westwicke.com
PR for investors
Stephanie Carrington – ICR Westwick IR
Email: stephanie.carrington@westwicke.com